» Articles » PMID: 27386326

Elevated C-reactive Protein is Associated with Disease Progression in Patients with Mild Crohn's Disease

Overview
Journal Springerplus
Date 2016 Jul 8
PMID 27386326
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Few studies have been conducted on the progression of mild Crohn's disease (CD). We aimed to investigate the natural course in mild CD patients with or without bowel damage, to identify predictors of bowel resection and to calculate the requirement for rescue medication.

Methods: A total of 104 patients with mild activity (150 < CDAI < 220) with or without bowel damage were identified from among 1050 CD patients between January 2008 and May 2014. Univariate and multivariate analysis was used to identify factors associated with bowel resection. The cumulative probabilities of bowel resection and rescue medication such as steroids or anti-TNF agents were calculated.

Results: The median follow-up duration was 28.2 months (IQR 26.7). Cumulative probabilities of bowel resection were 0.2, 11.8 and 42.4 % at 1, 3 and 5 years respectively. The CD patients with bowel damage had a higher bowel resection rate than those without bowel damage (P < 0.001). The cumulative probabilities of corticosteroid-requirement were 3.0, 19.6 and 78.4 % of patients at 1, 3 and 5 years, respectively, and 2.1, 11.9 and 56.1 %, in terms of the cumulative probabilities of requiring anti-TNF agents. Patients with elevated CRP (>1.6 mg/dL) were more likely to undergo bowel resection (P = 0.032).

Conclusions: Even in CD patients with mild disease activity, the cumulative probability of bowel resection is not low if they have bowel damage or elevated CRP at baseline. Mild CD patients with bowel damage or elevated CRP at baseline need special attention.

Citing Articles

Risk Factors of Recurrent Anal Abscess in Patients with Type 2 Diabetes Mellitus; a 4-Year Retrospective study.

Malekpour Alamdari N, Afaghi S, Esmaeili Tarki F, Fathi M, Besharat S, Rahimi F Arch Acad Emerg Med. 2022; 10(1):e69.

PMID: 36381972 PMC: 9637263. DOI: 10.22037/aaem.v10i1.1692.


Evaluation of the modified Crohn's disease activity index in patients with Crohn disease with enterostomy: A single-center observational study.

Ishida N, Miyazu T, Suzuki T, Tamura S, Tani S, Yamade M Medicine (Baltimore). 2021; 100(6):e24717.

PMID: 33578614 PMC: 10545123. DOI: 10.1097/MD.0000000000024717.


Involvement of Activated Cdc42 Kinase1 in Colitis and Colorectal Neoplasms.

Lv C, Zhao X, Gu H, Huang L, Zhou S, Zhi F Med Sci Monit. 2016; 22:4794-4802.

PMID: 27926694 PMC: 5158129. DOI: 10.12659/msm.902274.

References
1.
Dubinsky M, Lin Y, Dutridge D, Picornell Y, Landers C, Farrior S . Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol. 2006; 101(2):360-7. PMC: 2259248. DOI: 10.1111/j.1572-0241.2006.00456.x. View

2.
Wolters F, Russel M, Stockbrugger R . Systematic review: has disease outcome in Crohn's disease changed during the last four decades?. Aliment Pharmacol Ther. 2004; 20(5):483-96. DOI: 10.1111/j.1365-2036.2004.02123.x. View

3.
Dignass A, Van Assche G, Lindsay J, Lemann M, Soderholm J, Colombel J . The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis. 2010; 4(1):28-62. DOI: 10.1016/j.crohns.2009.12.002. View

4.
Desai D, Faubion W, Sandborn W . Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther. 2007; 25(3):247-55. DOI: 10.1111/j.1365-2036.2006.03184.x. View

5.
Click B, Vargas E, Anderson A, Proksell S, Koutroubakis I, Rivers C . Silent Crohn's Disease: Asymptomatic Patients with Elevated C-reactive Protein Are at Risk for Subsequent Hospitalization. Inflamm Bowel Dis. 2015; 21(10):2254-61. DOI: 10.1097/MIB.0000000000000516. View